Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-center, Randomized, Open-label, Dose-escalation Study to Determine Safety of Single (QD) and Multiple (3 QD) Doses of KAE609, Given to Adults With Uncomplicated Plasmodium Falciparum Malaria

Trial Profile

A Phase 2, Multi-center, Randomized, Open-label, Dose-escalation Study to Determine Safety of Single (QD) and Multiple (3 QD) Doses of KAE609, Given to Adults With Uncomplicated Plasmodium Falciparum Malaria

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cipargamin (Primary) ; Artemether/lumefantrine
  • Indications Falciparum malaria
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Aug 2021 Cohort 5 (150 mg single cipargamin dose) and an optional sixth cohort in which patients would receive 110 mg or 225 mg single doses, depending on hepatic safety in cohort 5, were added in a protocol amendment made when the trial was ongoing, as per results published in the Clinical Infectious Diseases.
    • 19 Aug 2021 Results assessing efficacy, pharmacokinetics, and resistance marker analysis across a range of cipargamin doses in adults in subSaharan Africa with uncomplicated plasmodium falciparum malaria, published in the Clinical Infectious Diseases.
    • 03 Jul 2021 Results assessing whehter high prevalence of P. falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine, published in the Journal of Infectious Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top